After two rejections, FDA approves AstraZeneca potassium drug

May 21, 2018

After two previous rejections, the FDA has approved AstraZeneca’s excess potassium drug, Lokelma.

AstraZeneca bought the drug’s original developer, ZS Pharma, for $2.7 billion in 2015. The drug was rejected twice by the FDA — once in May 2016 and again in March 2017 — due to unspecified manufacturing issues.

The approval is a big one for AstraZeneca, as it will give the drugmaker a rival hyperkalemia drug to Vifor Pharma’s Veltassa.

Read the press release